(Albany, USA) DelveInsight’s “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Lung Injury, historical and forecasted epidemiology as well as the Acute Lung Injury market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Acute Lung Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Lung Injury Market Forecast

 

Some of the key facts of the Acute Lung Injury Market Report: 

• The Acute Lung Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2020, there were 267,981 cases of acute lung injury (ALI) overall in the 7MM
• According to DelveInsight forecasts, there will be 201,587 instances of ALI in the United States in 2020, which is a higher incidence than previously thought
• Germany had the biggest incident population of ALI among the EU-5 nations in 2020, with 22,272 cases, followed by Italy with 12,719 instances. However, with 5,262 incidents, Spain had the lowest incident population in 2020
• Key Acute Lung Injury Companies: Asklepion Pharmaceuticals, LLC, Apeptico Forschung GMBH, Ono Pharmaceutical Co. Ltd, GlaxoSmithKline, Theravance Biopharma, Eli Lilly and Company, Windtree Therapeutics, Mallinckrodt, Faron Pharmaceuticals Ltd, and others
• Key Acute Lung Injury Therapies: L-citrulline, AP301, Sivelestat, GSK2586881, TD-0903, Sivelestat, Lucinactant, Nitric Oxide, Interferon Beta, and others
• The Acute Lung Injury epidemiology based on gender analyzed that the percentage of cases of Acute Lung Injury are equal in both the genders
• The Acute Lung Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Lung Injury pipeline products will significantly revolutionize the Acute Lung Injury market dynamics.

 

Acute Lung Injury Overview

Abrupt lung injury (ALI) is a syndrome that includes bilateral pulmonary infiltrates and abrupt hypoxemic respiratory failure. It is not exclusively caused by left atrial hypertension but is related with both pulmonary and non-pulmonary risk factors. According to the Berlin Definition, the category of acute lung damage was eliminated, and three severity categories for ARDS were established based on the P/F ratio: mild (range: 201–300), moderate (range: 101–200), and severe (range: 100mmHg). Thus, mild ARDS is the new definition of ALI.

 

Get a Free sample for the Acute Lung Injury Market Report 

https://www.delveinsight.com/sample-request/acute-lung-injury-market

 

Acute Lung Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acute Lung Injury Epidemiology Segmentation:

The Acute Lung Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Acute Lung Injury
• Prevalent Cases of Acute Lung Injury by severity
• Gender-specific Prevalence of Acute Lung Injury
• Diagnosed Cases of Episodic and Chronic Acute Lung Injury

 

Download the report to understand which factors are driving Acute Lung Injury epidemiology trends @ Acute Lung Injury Epidemiology Forecast

 

Acute Lung Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Lung Injury market or expected to get launched during the study period. The analysis covers Acute Lung Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Lung Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Acute Lung Injury Therapies and Key Companies

• L-citrulline: Asklepion Pharmaceuticals, LLC
• AP301: Apeptico Forschung GMBH
• Sivelestat: Ono Pharmaceutical Co. Ltd
• GSK2586881: GlaxoSmithKline
• TD-0903: Theravance Biopharma
• Sivelestat: Eli Lilly and Company
• Lucinactant: Windtree Therapeutics
• Nitric Oxide: Mallinckrodt
• Interferon Beta: Faron Pharmaceuticals Ltd

 

Discover more about therapies set to grab major Acute Lung Injury market share @ Acute Lung Injury Treatment Market

 

Scope of the Acute Lung Injury Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Lung Injury Companies: Asklepion Pharmaceuticals, LLC, Apeptico Forschung GMBH, Ono Pharmaceutical Co. Ltd, GlaxoSmithKline, Theravance Biopharma, Eli Lilly and Company, Windtree Therapeutics, Mallinckrodt, Faron Pharmaceuticals Ltd, and others
• Key Acute Lung Injury Therapies: L-citrulline, AP301, Sivelestat, GSK2586881, TD-0903, Sivelestat, Lucinactant, Nitric Oxide, Interferon Beta, and others
• Acute Lung Injury Therapeutic Assessment: Acute Lung Injury current marketed and Acute Lung Injury emerging therapies
• Acute Lung Injury Market Dynamics: Acute Lung Injury market drivers and Acute Lung Injury market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acute Lung Injury Unmet Needs, KOL’s views, Analyst’s views, Acute Lung Injury Market Access and Reimbursement 

 

To know more about Acute Lung Injury companies working in the treatment market, visit @ Acute Lung Injury Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Acute Lung Injury Market Report Introduction

2. Executive Summary for Acute Lung Injury

3. SWOT analysis of Acute Lung Injury

4. Acute Lung Injury Patient Share (%) Overview at a Glance

5. Acute Lung Injury Market Overview at a Glance

6. Acute Lung Injury Disease Background and Overview

7. Acute Lung Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Lung Injury 

9. Acute Lung Injury Current Treatment and Medical Practices

10. Acute Lung Injury Unmet Needs

11. Acute Lung Injury Emerging Therapies

12. Acute Lung Injury Market Outlook

13. Country-Wise Acute Lung Injury Market Analysis (2019–2032)

14. Acute Lung Injury Market Access and Reimbursement of Therapies

15. Acute Lung Injury Market Drivers

16. Acute Lung Injury Market Barriers

17.  Acute Lung Injury Appendix

18. Acute Lung Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services